Hemispherx Biopharma Inc Sample Contracts

CLASS B COMMON STOCK PURCHASE WARRANT hemispherx biopharma, inc.
Hemispherx Biopharma Inc • April 20th, 2018 • Biological products, (no disgnostic substances)

THIS CLASS B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 24, 2018 (the “Initial Exercise Date”) and on or prior to the close of business on five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Hemispherx BioPharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

AutoNDA by SimpleDocs
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • September 1st, 2016 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of August 30, 2016, between Hemispherx BioPharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, Rights Agent
Rights Agreement • November 20th, 2002 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • Delaware
WHEREAS:
Registration Rights Agreement • July 11th, 2005 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • Illinois
PRE-FUNDED COMMON STOCK PURCHASE WARRANT AIM ImmunoTech Inc.
AIM ImmunoTech Inc. • September 27th, 2019 • Biological products, (no disgnostic substances) • New York

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from AIM ImmunoTech Inc., a Delaware corporation (the “Company”), up to ______ shares of common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

by and among
Securities Purchase Agreement • January 27th, 2004 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York
ARTICLE 2 REPRESENTATIONS AND WARRANTIES
Supply Agreement • April 3rd, 2006 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • Washington
WARRANT
Hemispherx Biopharma Inc • August 6th, 2004 • Biological products, (no disgnostic substances)
PRE-FUNDED COMMON STOCK PURCHASE WARRANT AIM ImmunoTech Inc.
AIM ImmunoTech Inc. • September 6th, 2019 • Biological products, (no disgnostic substances) • New York

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from AIM ImmunoTech Inc., a Delaware corporation (the “Company”), up to ______ shares of common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

COMMON STOCK PURCHASE WARRANT AIM IMMUNOTECH INC.
Common Stock Purchase Warrant • September 27th, 2019 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from AIM ImmunoTech Inc., a Delaware corporation (the “Company”), up to ______ shares of common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

by and among
Securities Purchase Agreement • March 13th, 2003 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • April 1st, 2024 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 28, 2024, is entered into by and between AIM IMMUNOTECH, INC., a Delaware corporation (the “Company”), and ATLAS SCIENCES, LLC, a Utah limited liability company (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Equity Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • March 22nd, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of March 21, 2018, between Hemispherx BioPharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 19th, 2009 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of May 18, 2009, between Hemispherx Biopharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

AutoNDA by SimpleDocs
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • February 3rd, 2017 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of February 1, 2017, between Hemispherx BioPharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS:
Registration Rights Agreement • April 12th, 2006 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • Illinois
HEMISPHERX BIOPHARMA, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, Rights Agent Amended and Restated Rights Agreement Dated as of November 14, 2017
Rights Agreement • November 14th, 2017 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • Delaware

SECOND AMENDED AND RESTATED RIGHTS AGREEMENT, dated as of November 14, 2017 (the “Agreement”), between Hemispherx Biopharma, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Rights Agent” or “AST”).

Hemispherx Biopharma, Inc. and American Stock Transfer & Trust Company, LLC, as Warrant Agent Warrant Agency Agreement Dated as of March 8, 2019 WARRANT AGENCY AGREEMENT
Warrant Agency Agreement • March 8th, 2019 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York

WARRANT AGENCY AGREEMENT, dated as of March 8, 2019 (“Agreement”), between Hemispherx Biopharma, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability company (the “Warrant Agent”).

Contract
Common Stock Purchase • May 11th, 2009 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
COMMON STOCK PURCHASE WARRANT HEMISPHERX BIOPHARMA, INC.
Hemispherx Biopharma Inc • May 19th, 2009 • Biological products, (no disgnostic substances)

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May __, 2009 (the “Initial Exercise Date”) and on or prior to the close of business on the fifth anniversary of the date hereof (the “Termination Date”) but not thereafter, to subscribe for and purchase from Hemispherx Biopharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (the “Warrant Shares”) of Common Stock; provided, however, that the five year period set forth above as the Termination Date shall be extended for the number of days during such period in which (i) trading in the Common Stock is suspended by any Trading Market, or (ii) the Registration Statement is not effective but in no event later than October __, 2009. he purchase price of one share of Common Stock under this Warrant shall be equal to the Exer

COMMON STOCK PURCHASE AGREEMENT
Common Stock Purchase Agreement • July 8th, 2008 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • Illinois

COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of July 2, 2008, by and between HEMISPHERX BIOPHARMA, INC., a Delaware corporation (the “Company,” as further defined in Section 10), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL,...
AIM ImmunoTech Inc. • September 24th, 2019 • Biological products, (no disgnostic substances) • New York

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [_________], 2020 [DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT]. VOID AFTER 5:00 P.M., EASTERN TIME, [__________], 2024 [DATE THAT IS 4 YEARS COMMENCING ONE YEAR FROM THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT].

Hemispherx Biopharma, Inc. Equity Distribution Agreement
Equity Distribution Agreement • July 23rd, 2012 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York

Hemispherx Biopharma, Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as sales agent, shares of Common Stock, $0.001 par value per share, of the Company (the “Common Stock”) having an aggregate offering price of up to $75,000,000 (the “Shares”) on terms set forth herein. The Shares consist entirely of authorized but unissued shares of Common Stock to be issued and sold by the Company.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!